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Abstract
Objective The purpose of this study was to evaluate two MR-
guided biopsy techniques at 3 T, large core needle breast
biopsy(LCNB)andvacuum-assistedbreastbiopsy(VAB)and
to compare the diagnostic yield and rate of complications to
determine the optimal biopsy technique at 3 T.
Methods 55 LCNB and 64 VAB were consecutively
performed. Benign biopsy results were verified by retro-
spective correlation of histology, with pre-interventional,
post-interventional MRI studies and follow-up and were
classified as representative or non-representative. Time to
follow-up was up to 2 years for the considered non-
representative benign lesions. Statistical analysis was
performed using the Chi-squared test.
Results LCNB was technically successful in 100% of
patients (55/55) and VAB in 98% of patients (63/64).
Histopathological analysis resulted in 45 (82%) benign, 3
(5%) high-risk and 7 (13%) malignant lesions for LCNB
and 43 (67%) benign, 3 (5%) high-risk and 18 (28%)
malignant lesions. Distribution was significantly different
(p<0.001), favouring VAB over LCNB.
Conclusion Because of the substantially higher diagnostic
yield and certainty of a benign diagnosis, VAB is the
optimal biopsy technique at 3 T. LCNB should be
considered when VAB is not feasible.
Keywords Breast cancer.Biopsy.MRI.High field.
Neoplasms
Introduction
The use of Magnetic Resonance Imaging (MRI) for the
detection and evaluation of breast lesions continues to
increase. MRI of the breast has high sensitivity and lower
specificity in the evaluation of breast lesions, with
sensitivity of 90% and a specificity of 72% [1].
The increasing use of magnets with high field strength
(3 Tesla [T] and over) in clinical practice is very suitable.
With the high signal-to-noise ratio of these systems,
appropriate acquisitions can be used to achieve high spatial
and temporal resolution that allows depiction of lesion
morphology and lesion enhancement with unprecedented
accuracy [2–4]. Compared with the results of 1 T and 1.5 T
MRI in the literature, 3 T may have an even higher
sensitivity to breast cancer [5]. Nevertheless, even at 3 T it
is often not possible to separate malignant from benign
findings purely on imaging characteristics alone. Accurate
diagnosis of these lesions requires histological evaluation.
Magnetic resonance imaging of the breast reveals
suspicious lesions occult at target ultrasound or mammog-
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MRI breast lesions MRI-guided biopsy is the technique of
choice. Moreover, MRI-guided biopsy is indicated in all
lesions where an ultrasound or mammographically detected
and biopsied lesion is possibly not the same lesion as that
detected at MRI. The demand for MRI-guided breast
interventions is growing owing to the increasing use of
breast MRI in clinical practice.
Magnetic resonance-guided tissue sampling of suspicious
MRI breast lesions, can be accomplished by fine-needle
aspiration, wire localisation followed by surgical excision,
large core-needle biopsy (LCNB), or by vacuum-assisted
biopsy (VAB) [8, 9].
Magnetic resonance-guided LCNB using 14 G needles
and VAB have both been described as suitable techniques
for MRI-guided breast biopsy at 1.5 T [10–21]. At 3 T only
MRI-guided LCNB has been evaluated [22, 23]. Moreover,
no studies directly compare the diagnostic yield of LCNB
with VAB at any field strength. In this retrospective study
we evaluated both methods at 3 T and compared the
diagnostic yield and rate of complications to determine the
optimal biopsy technique at 3 T.
Materials and methods
Patient characteristics
Patients derive from a diagnostic population, who presented
with an MRI-detected lesion between July 2007 and
February 2010, not visualised at second-look ultrasound
or in whom second-look ultrasound could not reliably
reproduce the lesion, were scheduled for MRI-guided
biopsy at 3 T. Before October 2008 14 G LCNB were
performed, thereafter 9 G VAB was the principal method.
We retrospectively analysed the data from a total of 147
consecutive women (mean age; range: 51; 29–71 years)
with 155 suspicious breast lesions at our hospital, in this
period. Indications for breast MRI are shown in Table 1.
Patients were referred for MRI-guided biopsy from 22
different hospitals. Patients with a breast MRI from a
different hospital, had a second reading from a MRI-breast
radiologist in our institution, before the biopsy. In doubtful
cases an additional diagnostic breast-MRI was performed in
our institution.
The level of suspicion was reported on a scale of 0–6,
identical to that in the lesion-assessment categories used in
the breast imaging reporting and data system (BI-RADS)
[24]. Numeric categories were the following: 0, needs
additional imaging evaluation; 1, normal; 2, benign; 3,
probably benign; 4, suspicious; 5, highly suggestive of
malignancy; 6 proven malignancy. Classification was based
on lesion morphology and enhancement kinetics [25]. For
lesions interpreted as probably benign, suspicious or highly
suggestive of malignancy on MRI, correlative ultrasound
was performed to determine if the lesion was ultrasono-
graphically evident and, thereby amenable to tissue sampling
under ultrasound guidance. All patients with a BIRADS 3, 4
or 5 lesions that were ultrasonographically occult were
scheduled for a MRI-guided breast biopsy. In 80% of the
biopsiedcases there was a masslesion, in13% ofthe biopsied
cases there was non mass like enhancement and in 7% of the
cases there was a focus.
All MRI-guided breast biopsies were performed in a
clinical setting. The study has been carried out in the
Netherlands in accordance with the applicable rules
concerning the review of research ethics committees and
informed consent.
MRI-guided biopsy procedure and equipment
All biopsies were performed on a Siemens Magnetom Trio
system, using a dedicated four-channel open breast coil
(Invivo Interventional Instruments, Wurzburg, Germany),
with an add-on device for needle positioning (Noras,
Germany).
Patients were positioned on the MRI table in the prone
position with the affected breast compressed in the biopsy
device to avoid motion during the biopsy procedure. All
patients underwent imaging before and three times after the
administration of 0.1 mmol/kg contrast agent (DOTAREM,
Guerbet, France), using a T1-weighted Fast Low Angle
Shot (FLASH) 3D acquisition that lasted 98 s and provided
coverage of both breasts with near isotropic voxels of
0.9*0.9*1 mm to allow image reconstruction in any plane.
The main parameters of this MRI sequence are listed in
Table 2. A dedicated computer program (DynaCAD,
Invivo, Germany) was used to obtain coordinates of the
lesion and guidance for needle positioning (Figs. 1 and 2).
After initial imaging, the table was moved out of the bore
and local anaesthesia (lidocaine 1%) was administered after
disinfection of the breast. A small incision was made in the
Table 1 Indication for MRI examination in 147 patients
Number
High risk screening 54 (37%)
–Positive family history or BRCA positive 48
–History of high risk lesion or cancer 6
Problem solving 43 (29%)
–Questionable lesion mammography/ultrasound 36
–Positive axillary node, unknown primary 7
Staging of known breast cancer 50 (34%)
342 Eur Radiol (2012) 22:341–349skin and the needle (LCNB or VAB) was inserted into the
breast. ThepositionofthedevicewasevaluatedwithaFLASH
3D and another FLASH 3D was obtained immediately
post-biopsy to correlate the biopsy cavity (at LCNB)
and the marker (at VAB, ATEC TriMark, Indianapolis,
IN, USA) with the position of the lesion.
MRI-guided large core needle biopsy
Large core-needle biopsy was performed with 14-gauge
titanium needles using a post and pillar system that allowed
angulation of the biopsy tract up to 30° (Fig. 3).
Through a sterile 12-gauge needle holder a 12-gauge
coaxial needle was inserted in the breast (CoaxNeedle
Highfield 12 G-11.1 mm; Invivo Interventional Instruments).
In the event of good correlation the patient was moved out of
the bore of the magnet. Between 5 and 6 biopsies were
taken with a disposable 14 G semi-automatic Highfield
MRI compatible biopsy gun (Invivo Interventional
Instruments).
MRI-guided vacuum-assisted biopsy
Vacuum-assisted biopsy were performed with one of two
commercially available MRI-compatible VAB devices:
Table 2 Biopsy protocol
TE/TR (ms) 2.62/735
Flip angle 13°
Fat suppression none
Field of view (mm
2) 340×170
Effective slice thickness (mm) 1
Number of acquisitions 1 before and 3 after contrast medium
Number of slices 160/acquisition
Acquired voxel size (mm
3) 0.9×0.9×1
Temporal resolution (s) 98
Fig. 1 Screenshot from a
biopsy procedure, using a 14 G
large core needle to biopsy an
non-mass-like area of enhance-
ment in the upper outer quadrant
of the left breast. The lower
screen shows how to position
the post and pillar device. The
coordinates for optimal needle
position can be read from the
bottom of the screen
Eur Radiol (2012) 22:341–349 343eithera10-gaugeVABsystem(SenorRx;Irvine,CA,USA)or
a 9-gauge VAB system (ATEC Suros, Indianapolis, IN,
USA). We used a grid system with a needle block as
supplied by the manufacturer; this approach did not allow
angulation (Fig. 4).
A coaxial sheath was placed using a 9-gauge or 10-gauge
titanium stylet in the appropriate grid location. The stylet was
replacedbyasterileplasticMRI-visibleobturator.IfaFLASH
3D proved a good correlation, the plastic obturator was
replaced by one of the respective VAB devices and up to 12
biopsies were taken.
Data collection and statistic analysis
Of the 147 patients with suspicious breast lesions, 4
patients had two lesions and 2 patients had three lesions.
Thirteen lesions were biopsied twice with the same
technique VAB or LCNB. A total of 168 suspected lesions
were scheduled for an MRI-guided biopsy, 41 BIRADS 3
Fig. 3 Post and pillar biopsy system with LCB system in place, note
that the needle is angulated towards the thoracic wall. The blue device
at the post and pillar system is a needle sleeve that can be used to lock
the co-axial needle in one position when the biopsy needle is inserted
and removed to obtain multiple samples
Fig. 2 Screenshot from a
biopsy procedure using a 9 G
vacuum-assisted needle to
biopsy a small mass-like lesion
with an irregular margin at six
o’clock in the left breast. The
lower screen shows where to put
the needle block (purple square)
and which hole to use (orange
dot) in order to come closest to
the optimal position (red circle).
The required depth can be read
at the bottom of the screen
(arrow)
344 Eur Radiol (2012) 22:341–349lesions, 111 BIRADS 4 lesions and 16 BIRADS 5 lesions.
In 26 patients the procedure was cancelled. Eighteen
biopsies were excluded because they were judged as not
representative lesions after histopathologic analysis, an
extra 4 biopsies were excluded because of losses to
follow-up and 1 biopsy was excluded because of technical
failure. Finally we included 55 LCNB and 64 VAB in a
consecutive series of patients scheduled for MRI-guided
breast biopsy (Fig. 5). Of the 64 VAB, 35 biopsies were
performed with the 10-gauge VAB system (SenorRx) and
the other 29 biopsies were performed with a 9-gauge VAB
system (ATEC Suros).
All biopsies were performed by three experienced MRI-
breast radiologists who had a lot of experience with MRI-
guided LCNB and less with MRI-guided VAB. All three
radiologist had more than 3 years experience with MRI-
guided LCNB and had done more than 50 procedures each.
MRI-guided VAB was only done at 1.5 T for 1 year and all
three radiologist had done about 10 procedures each, before
they started to do the same procedure at 3 T.
We assessed technical success rates, where technical
success was defined as:
1. It is possible to get the needle on the right spot
2. The biopsy can be safely performed according to the
performing physician
3. The lesion was removed completely or partially
according to the post-VAB imaging.
We judged VAB not possible, if the risk of skin tears, severe
bleeding, or severe pain in the patient was high. Complications,
such as pain and arterial bleeds were registered and were in this
study not considered as technical unsuccessful.
After histopathological analysis, the lesions were classified
in three categories: benign, high-risk or malignant. Malignant
lesions and high-risk lesions were surgically removed. In the
case of a benign lesion, the images of the biopsy procedure
were re-evaluated to determine whether the tissue samples
were representative and at least 6-month follow-up MRI was
recommended. Total time to follow-up was 2 years in case of
unchanged lesions.
Statistical analysis was done with SPSS 12.0 and using
the Mann–Whitney U test. Significance was assumed at a
level of p<0.05.
Fig. 4 Grid system with VAB system in place, note that no angulation
is possible. The computer program indicates where to put the needle
block and which hole to use to perform the most accurate biopsy
147 patients with 155 lesions 
and 168 scheduled biopsies 
26 scheduled biopsies were cancelled
43 benign 
lesions (67%) 
3 high-risk 
lesions (5%) 
64 VAB 
3 high-risk 
lesions (5%) 
18 malignant 
lesions (28%) 
45 benign 
lesions (82%) 
7 malignant 
lesions (13%) 
55 LCNB 
119 biopsies
18 biopsies excluded: non-representative 
results   
4 biopsies excluded: losses to follow-up.
1 biopsy excluded: technical failure
Fig. 5 Flowchart showing
MRI-guided biopsies and
histopathological results
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Technical success
In our patient series, LCNB was technically successful in
100% of patients (55/55) and VAB was technically
successful in 98% of patients (63/64) (n.s.).
According to the post-interventional imaging 1 of the 72
VAB procedures was unsuccessful and immediate rebiopsy
was performed. Assessment was considered impaired, but
successful in 1 LCNB procedure and 3 VAB procedures
(n.s.). Motion artefacts occurred in 1 patient at LCNB.
Histological analysis of the lesion revealed normal breast
tissue. After more than 1 year of follow-up, no signs of
malignancy were found.
Using VAB 2 small arterial haemorrhages that required
prolonged manual compression were recorded (Fig. 6). In
one patient no marker could be placed because the patient
could no longer lie in the prone position.
The lesion size ranged from 3 to 28 mm with a median
lesion size of 12 mm, 50% were smaller than 1 cm (28
LCNB and 32 VAB) and 8% of all the lesions were smaller
than 5 mm (foci) and were all biopsied with MRI-guided
VAB.
Clinical results
Final histology results obtained in 55 LCNB and 64 VAB
procedures are listed in Table 3.
In the LCNB group histopathological analysis of the
biopsy samples resulted in benign lesions in 45/55 (82%),
in high-risk lesions in 3/55 (5%) and in malignant lesions in
7/55 (13%). In the VAB group this resulted in 43/64 (67%)
benign lesions, 3/64 (5%) and 18/64 (28%) malignant
lesions (Fig. 5).
Discussion
We evaluated LCNB and VAB using a 3 T clinical MR
system and compared the diagnostic yield and rate of
complications to determine the optimal biopsy technique
at 3 T.
Published data on the use of MRI-guided biopsy at 1.5 T
reported a technical success rate of 95% to 100% and
cancer yields ranging from 20% to 56% for LCNB [10, 11,
15], and a technical success rate of 96% to 100% and
cancer yields ranging from 24% to 40% for VAB [16–21].
These numbers are comparable to the accepted rates
reported in mammography- and ultrasound-guided proce-
dures [8]. In our patient series, in the LCNB group 13%
were found to be malignant after biopsy and 28% in the
Magnetic resonance-guided LCNB using 14 G needles at
1.5 T have been reported by several groups [10–15]. Kuhl
et al. [10] reported the largest series of MRI-guided LCNB
in 59 patients with 78 lesions. One carcinoma was missed,
and histological underestimations were not observed. Chen
et al. [11] reported 34 successful LCNB in 35 lesions in 29
women and 6% (2/35) were underestimated carcinoma.
Two lesions with atypical ductal hyperplasia were upgraded
to malignancy after surgery. In a multicentre European trial
Perlet et al. [18] reported successful VAB in 517 (96%) of
538 lesions. Histological underestimation was observed in
8 patients (2%). An upgrade was noted in 5 patients who
had a diagnosis of ADH, and in 3 patients who had a
diagnosis of DCIS.
The biopsies we performed, 20% of the LCNB were
considered unrepresentative biopsies and were excluded
Fig. 6 Biopsy of a small irregular lesion at 6 o’clock in the left breast
using a 9 G vacuum-assisted needle. a subtraction image created
before the biopsy procedure to localise the lesion. b placement of the
coaxial sheet, the trocar has been removed and replaced with a plastic
insert. c the same coaxial sheet directly after the biopsy, note the large
haematoma that surrounds the tip of the needle (double-headed
arrow). d A large marker is left that also provides some compression
from the inside. Histopathological results revealed a complex sclerosing
lesion with cystic degeneration. No malignancy was found
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V AB group. LCNB was technically successful in 100% of
patients (55/55) and V AB was technically successful in 98%
of patients (63/64), but more importantly V AB was
significantly more often representative than LCNB.from this study. After chirurgical excision biopsy 7% of
carcinomas were missed and histological underestimation
was present in 6%. VAB showed 4 unrepresentative
biopsies, 2 missed carcinomas and histological underestima-
tion was not observed. Eight of the 14 non-representative
LCNB were smaller than 1 cm (57%). Therefore, LCNB
biopsy at 3 T is not recommended for lesions smaller than
10 mm.
Two of our VAB procedures were converted to LCNB
because of the location of the lesion (too close to the skin
and the other lesion was too close to the chest wall), which
is in part attributable to the more rigid biopsy technique
with the grid system. Using angulation of the needle will
probably allow VAB in a number of patients in whom the
technique first failed. In another patient scheduled for
LCNB a 14 G needle could not enter the breast because of
the solid consistency of the breast. Finally a successful
biopsy was performed with an 18 G needle.
The chance of detecting malignancy is very much
dependent on the à priori chance of the biopsied lesion
being malignant. It is important to realise that it is essential
to compare the results of the pathological analysis of the
biopsy specimen with the lesion seen at MRI. A diagnosis
of fibrosis with chronic inflammation is usually acceptable
in lesions with no mass effect classified as BI-RADS 3 to
BI-RADS 4a. However, this diagnosis is absolutely
insufficient in lesions classified as BI-RADS 5, as well as
in any lesion presenting as a clear mass.
For BIRADS III (probably benign) lesions, at mammog-
raphy a 6-month short-term follow-up is recommended,
because the frequency of carcinoma in these lesions is low,
ranging from 0.5% to 2% [26–29]. Published results show a
wide range of cancer yields (0.6% to 10%) among probably
benign MRI lesions [30–35]. There are a few indications
for which mammographic stereotactic biopsy of BIRADS
III lesions may be considered, such as when follow-up is
compromised or not available, in the instance of planned
pregnancy, or for patient anxiety [27, 36–38]. Eighteen
percent (41 lesions) of all the MRI-guided biopsied lesions
were classified as BIRADS III breast lesions, because a lot
of women nowadays do not except a 6 month follow-up
and prefer a biopsy directly. Three percent of these lesions
were found malignant at histopathologic analysis.
Magnetic resonance-guided LCNB using 14 G needles
and VAB have both been described as suitable techniques
for MRI-guided breast biopsy at 1.5 T [8, 9], although
several potential limitations of LCNB have been described
at 1.5 T or lower [9]. Compared with 1.5 T, at 3 T an extra
potential limitation of the LCNB technique has been
described by Peters et al. [22]. Susceptibility artefacts
increase with increasing field strength. This can cause a
substantial signal void around the 14 G needle when
performing MRI-guided LCNB at 3 T.
The certainty of the histopathological diagnosis increases
with an increase in the amount of tissue extracted, especially
in a situation where there is no real-time feedback of the
needle position during biopsy, as is the case in MRI-guided
breast biopsy. In lesions with no mass effect LCNB may not
sampleenoughmaterialtoascertaindiagnosis.Inmasslesions
the non-rigid breast tissue may allow a small solid lesion to
move during biopsy, causing the needle to pass right beside
the lesion, rather than through its core.
Our study has several limitations. First of all in our study
population most patients with a representative benign lesion
had a 6 month follow-up instead of a 24 months follow up
which is necessary to make them eligible to be considered
as truly benign.
An important limitation of this study isthe factthatthe two
biopsy techniques were compared in a sequential and not in a
parallel way. Lots of covariates could influence the results of
the two study arms, the most important being the fact that
experience was much higher for the second biopsy technique,
resulting in a much steeper learning curve and possibly better
results.Alsothefactthattwodifferentvacuumassistedbiopsy
devices have been used is another potential limitation as the
study subgroup becomes heterogeneous.
In our study up to 12 VAB were taken instead of >24
core (11-Gauge) specimens, which is recommended in the
latest European consensus meeting [39].
Another very important limitation is the highly hetero-
geneous study population. The fact that patients were
Table 3 Histological findings
Lesion findings LCNB (n=55) VAB (n=64)
No. % No. %
Malignant 7 13 18 28
IDC 3 5 10 16
ILC 3 5
DICS 4 7 5 7
High-risk 3 5 3 5
LCIS 3 5 3 5
Benign 45 82 43 67
Fibroadenoma 3 5 5 7
Sclerosing adenosis 2 4 4 6
Lymph node 2 4 1 2
Radial scar 2 4 2 3
Papilloma 1 2
Normal breast tissue 21 38 12 19
Others 14 25 19 30
IDC Invasive Ductal Carcinoma
ILC Invasive Lobular Carcinoma
DCIS Ductal Carcinoma In Situ
LICS Lobular Carcinoma In Situ
Eur Radiol (2012) 22:341–349 347referred from 22 different hospitals for MRI-guided biopsy and
the consecutively study population is a major limitation.
Although all breast MRI’s from the different hospitals, had a
second reading from aMRI-breast radiologist in our institution,
beforethebiopsyandindoubtful cases an additional diagnostic
breast MRI was made in our institution, it is unthinkable that
equalclinicalguidelinesforsuchreferralsapplyforallhospitals
or that experience levels match for all those different
radiologists.
Finally, by the time we started with MRI-guided LCNB
at 3 T, large core needles with 14 G were not anymore
recommended for MRI-guided biopsy at 1.5 T [8, 9].
Compared with the results of 1 T and 1.5 T MRI in the
literature, 3 T may have higher sensitivity in the detection
of breast cancer [5]. Nevertheless the specificity is
comparable with the results of 1.5 T [5]. Demand for
adequate MRI-guided tissue sampling remains, also at high
field strength. Our study shows that MRI-guided VAB
should be used for all MRI-guided breast biopsies at 3 T
because of the substantially higher diagnostic yield and
increased certainty of a benign diagnosis, compared with
LCNB. LCNB should be considered when VAB is
unavailable or not feasible.
Open Access This article is distributed under the terms of the
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